CL2A-SN-38 是一种药物-接头偶联物，由一种有效的 DNA 拓扑异构酶 I 抑制剂 SN-38 和接头 CL2A 组成，用于制造抗体药物偶联物。它对一系列人类实体瘤类型提供显着和特异性的抗肿瘤作用。

CL2A-SN-38 is a drug-linker conjugate consisting of SN-38, a potent DNA topoisomerase I inhibitor, and linker CL2A, for the manufacture of antibody drug conjugates (ADCs). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a nonclaevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond[1].

1279680-68-0

C73H97N11O22

1480.61

DMSO:85 mg/mL (57.4 mM),Need ultrasonic
DMSO:100 mg/mL (67.54 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years